(Q37844573)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21332415%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

review article

1 reference

title

Novel therapy in Parkinson's disease: adenosine A(2A) receptor antagonists (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21332415%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

1 reference

Zsigmond Tamás Kincses

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21332415%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Laszlo Vecsei

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21332415%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

author name string

Nikoletta Szabó

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21332415%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

language of work or name

English

0 references

publication date

19 February 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21332415%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Drug Metabolism & Toxicology

22 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21332415%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21332415%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21332415%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

page(s)

441-455

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21332415%20AND%20SRC:MED&resulttype=core&format=json

Alzheimer's disease and Parkinson's disease

22 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Concentric hyalin intraneuronal inclusions of Lewy type in the brains of elderly persons (50 incidental cases): relationship to parkinsonism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Staging of brain pathology related to sporadic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Electrophysiological correlates of visual categorization: evidence for cognitive dysfunctions in early Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Corticostriatal circuitry mediates fast-track visual categorization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Geographical difference in Parkinson's disease prevalence within West Scotland

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Familial and environmental risk factors in Parkinson's disease: a case-control study in north-east Italy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Multiple risk factors for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Conversion from sustained release carbidopa/levodopa to carbidopa/levodopa/entacapone (stalevo) in Parkinson disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Dopaminergic neurons intrinsic to the striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

The dopamine agonist cabergoline provides neuroprotection by activation of the glutathione system and scavenging free radicals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Pergolide scavenges both hydroxyl and nitric oxide free radicals in vitro and inhibits lipid peroxidation in different regions of the rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Protective effect of talipexole on MPTP-treated planarian, a unique parkinsonian worm model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Pramipexole protects against MPTP toxicity in non-human primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: involvement of the glutathione system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

The effect of deprenyl and levodopa on the progression of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

A double-blind, delayed-start trial of rasagiline in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Inhibitory effect of MK-801 on amantadine-induced dopamine release in the rat striatum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Effect of transcranial magnetic stimulation on Parkinson motor function--systematic review of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Blocking striatal adenosine A2A receptors: a new strategy for basal ganglia disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Autoradiographic evidence for G-protein coupled A2-receptors in rat neostriatum using [3H]-CGS 21680 as a ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Binding of the adenosine A2 receptor ligand [3H]CGS 21680 to human and rat brain: evidence for multiple affinity sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Adenosine A2 receptors: selective localization in the human basal ganglia and alterations with disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Distribution of adenosine receptors in the postmortem human brain: an extended autoradiographic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Localization of adenosine A2A-receptors in rat brain with [3H]ZM-241385.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Cellular expression of adenosine A2A receptor messenger RNA in the rat central nervous system with special reference to dopamine innervated areas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Adenosine A2a receptor mRNA is expressed by enkephalin cells but not by somatostatin cells in rat striatum: a co-expression study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Anatomy of adenosine A2A receptors in brain: morphological substrates for integration of striatal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: implications for striatal neuronal function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Metabotropic glutamate mGlu5 receptor-mediated modulation of the ventral striopallidal GABA pathway in rats. Interactions with adenosine A(2A) and dopamine D(2) receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Reciprocal interactions between adenosine A2A and dopamine D2 receptors in Chinese hamster ovary cells co-transfected with the two receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Inhibition by KF17837 of adenosine A2A receptor-mediated modulation of striatal GABA and ACh release

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

A2A receptor and striatal cellular functions: regulation of gene expression, currents, and synaptic transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Adenosine A(2A) receptor enhances GABA(A)-mediated IPSCs in the rat globus pallidus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Adenosine A2a receptor modulation of electrically evoked endogenous GABA release from slices of rat globus pallidus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Systemic administration of adenosine A(2A) receptor antagonist reverses increased GABA release in the globus pallidus of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Modulation of the striato-pallidal pathway by adenosine A2a receptors depends on dopaminergic striatal input

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Striatal A2A adenosine receptors differentially regulate spontaneous and K+-evoked glutamate release in vivo in young and aged rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

The role of kynurenines in disorders of the central nervous system: possibilities for neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

SCH 58261 (an adenosine A(2A) receptor antagonist) reduces, only at low doses, K(+)-evoked glutamate release in the striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Modulation of glutamate release and excitotoxicity by adenosine A2A receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Adenosine A2A receptor blockade differentially influences excitotoxic mechanisms at pre- and postsynaptic sites in the rat striatum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Adenosine A2A receptor antagonism increases striatal glutamate outflow in dopamine-denervated rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

2-Phenylaminoadenosine stimulates dopamine synthesis in rat forebrain in vitro and in vivo via adenosine A2 receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Adenosine agonists can both inhibit and enhance in vivo striatal dopamine release.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Presynaptic Adenosine A2and N-Methyl-D-Aspartate Receptors Regulate Dopamine Synthesis in Rat Striatal Synaptosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Adenosine A1 and A2 receptors modulate extracellular dopamine levels in rat striatum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Effect of the adenosine A2A receptor antagonist 8-(3-chlorostyryl)caffeine on L-DOPA biotransformation in rat striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Antagonism of adenosine A2A receptors underlies the behavioural activating effect of caffeine and is associated with reduced expression of messenger RNA for NGFI-A and NGFI-B in caudate-putamen and nucleus accumbens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Adenosine A1 and A2A receptor antagonists stimulate motor activity: evidence for an increased effectiveness in aged rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Lack of tolerance to motor stimulant effects of a selective adenosine A(2A) receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

SCH 58261, an A(2A) adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

The adenosine A2A antagonist KF17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: possible relevance to parkinsonism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Differential effects of adenosine antagonists in two models of parkinsonian tremor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Blockade of adenosine A2A receptors antagonizes parkinsonian tremor in the rat tacrine model by an action on specific striatal regions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

8-(3-Chlorostyryl)caffeine may attenuate MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A2A receptor antagonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Adenosine A2A antagonism reverses levodopa-induced motor alterations in hemiparkinsonian rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Premorbid smoking, alcohol consumption, and coffee drinking habits in Parkinson's disease: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

A case-control study on cigarette, alcohol, and coffee consumption preceding Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Dose-dependent protective effect of coffee, tea, and smoking in Parkinson's disease: a study in ethnic Chinese.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Diet and Parkinson's disease. I: A possible role for the past intake of specific foods and food groups. Results from a self-administered food-frequency questionnaire in a case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Nutritional and occupational factors influencing the risk of Parkinson's disease: a case-control study in southeastern Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Smoking, alcohol, and coffee consumption preceding Parkinson's disease: a case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Association of coffee and caffeine intake with the risk of Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Prospective study of caffeine consumption and risk of Parkinson's disease in men and women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Caffeine, postmenopausal estrogen, and risk of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Protective effect of caffeine against neurodegeneration in a model of Parkinson's disease in rat: behavioral and histochemical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Genetic and pharmacological inactivation of the adenosine A2A receptor attenuates 3-nitropropionic acid-induced striatal damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Tissue distribution of adenosine receptor mRNAs in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Positron emission tomography analysis of [11C]KW-6002 binding to human and rat adenosine A2A receptors in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Impaired expression of brain natriuretic peptide gene in diabetic rats with myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Characterization of the Potent and Highly Selective A(2A) Receptor Antagonists Preladenant and SCH 412348 [7-[2-[4-2,4-Difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyraz olo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in Rodent Models of

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Antagonists of the human A(2A) adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

An open-label, positron emission tomography study to assess adenosine A2A brain receptor occupancy of vipadenant (BIIB014) at steady-state levels in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Myoclonus of peripheral origin: two case reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

ST 1535: a preferential A2A adenosine receptor antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Water-soluble phosphate prodrugs of 1-propargyl-8-styrylxanthine derivatives, A(2A)-selective adenosine receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Injections of the selective adenosine A2A antagonist MSX-3 into the nucleus accumbens core attenuate the locomotor suppression induced by haloperidol in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Tremorolytic effects of adenosine A2A antagonists: implications for parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Quantification of indirect pathway inhibition by the adenosine A2a antagonist SYN115 in Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Potent and selective adenosine A2A receptor antagonists: 1,2,4-Triazolo[1,5-c]pyrimidines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Industry forum: Progress in pursuit of therapeutic A2A antagonists: The adenosine A2A receptor selective antagonist KW6002: Research and development toward a novel nondopaminergic therapy for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066

Electrophysiological and behavioural evidence for an antagonistic modulatory role of adenosine A2Areceptors in dopamine D2receptor regulation in the rat dopamine-denervated striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.557066